Noppachai Siranart, Christopher C Thompson, Marvin Ryou, Steven N Steinway
{"title":"Endoscopic Choledochoduodenostomy Versus Gallbladder Drainage for Malignant Biliary Obstruction: A Propensity Score Matched Study.","authors":"Noppachai Siranart, Christopher C Thompson, Marvin Ryou, Steven N Steinway","doi":"10.1007/s10620-025-09417-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic ultrasound-guided gallbladder drainage (EUS-GB) is an emerging alternative to choledochoduodenostomy (EUS-CBD) for malignant distal biliary obstruction (MDBO), particularly when conventional access is not feasible.</p><p><strong>Methods: </strong>We conducted a multicenter, retrospective study of patients undergoing EUS-GB or EUS-CBD for MDBO between January 2015 and October 2024. Primary outcomes were technical and clinical success. Secondary outcomes included procedural time, 6-month reintervention, adverse events (AEs), and all-cause mortality. Propensity score matching (PSM) was used to adjust for baseline differences.</p><p><strong>Results: </strong>Eighty-two patients were included (22 EUS-GB, 60 EUS-CBD). Technical success was comparable between groups (95.5% vs. 96.7%). EUS-GB was used as salvage in 50% of cases when EUS-CBD was not feasible, with a 90.9% technical success rate. PSM yielded 21 matched pairs. After propensity score matching, clinical success was similar (95.2% EUS-GB vs. 85.7% EUS-CBD, p = 0.61). EUS-GB had significantly lower 6-month reintervention (4.8% vs. 23.8%, p = 0.004) and stent-related complications (0% vs. 18.9%). Adverse event rates and all-cause mortality were similar. Median follow-up was 116 days (IQR: 51-300). In the EUS-GB group, pre-procedural cystic duct patency predicted clinical success (94.1%).</p><p><strong>Conclusion: </strong>EUS-GB is a technically effective and clinically comparable alternative to EUS-CDS for MDBO, with significantly fewer reinterventions and stent-related complications. When cystic duct patency is confirmed on imaging, EUS-GB may be considered as a primary approach or salvage strategy for biliary drainage in MDBO.</p>","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive Diseases and Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10620-025-09417-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Endoscopic ultrasound-guided gallbladder drainage (EUS-GB) is an emerging alternative to choledochoduodenostomy (EUS-CBD) for malignant distal biliary obstruction (MDBO), particularly when conventional access is not feasible.
Methods: We conducted a multicenter, retrospective study of patients undergoing EUS-GB or EUS-CBD for MDBO between January 2015 and October 2024. Primary outcomes were technical and clinical success. Secondary outcomes included procedural time, 6-month reintervention, adverse events (AEs), and all-cause mortality. Propensity score matching (PSM) was used to adjust for baseline differences.
Results: Eighty-two patients were included (22 EUS-GB, 60 EUS-CBD). Technical success was comparable between groups (95.5% vs. 96.7%). EUS-GB was used as salvage in 50% of cases when EUS-CBD was not feasible, with a 90.9% technical success rate. PSM yielded 21 matched pairs. After propensity score matching, clinical success was similar (95.2% EUS-GB vs. 85.7% EUS-CBD, p = 0.61). EUS-GB had significantly lower 6-month reintervention (4.8% vs. 23.8%, p = 0.004) and stent-related complications (0% vs. 18.9%). Adverse event rates and all-cause mortality were similar. Median follow-up was 116 days (IQR: 51-300). In the EUS-GB group, pre-procedural cystic duct patency predicted clinical success (94.1%).
Conclusion: EUS-GB is a technically effective and clinically comparable alternative to EUS-CDS for MDBO, with significantly fewer reinterventions and stent-related complications. When cystic duct patency is confirmed on imaging, EUS-GB may be considered as a primary approach or salvage strategy for biliary drainage in MDBO.
超声内镜引导下的胆囊引流术(EUS-GB)是恶性胆道远端梗阻(MDBO)治疗中替代胆总管十二指肠吻合术(EUS-CBD)的一种新兴方法,特别是在常规途径不可行的情况下。方法:我们对2015年1月至2024年10月期间接受EUS-GB或EUS-CBD治疗MDBO的患者进行了一项多中心回顾性研究。主要结果是技术和临床成功。次要结局包括手术时间、6个月再干预、不良事件(ae)和全因死亡率。倾向评分匹配(PSM)用于调整基线差异。结果:纳入82例患者(22例EUS-GB, 60例EUS-CBD)。技术成功率在两组间具有可比性(95.5%对96.7%)。当EUS-CBD不可行时,50%的病例采用EUS-GB进行救助,技术成功率为90.9%。PSM得到21对配对。倾向评分匹配后,临床成功率相似(95.2% EUS-GB vs. 85.7% EUS-CBD, p = 0.61)。EUS-GB的6个月再干预率(4.8% vs. 23.8%, p = 0.004)和支架相关并发症(0% vs. 18.9%)显著降低。不良事件发生率和全因死亡率相似。中位随访时间为116天(IQR: 51-300)。在EUS-GB组中,术前胆囊管通畅预测临床成功(94.1%)。结论:EUS-GB是一种技术上有效且临床可比较的替代EUS-CDS治疗MDBO的方法,可显著减少再干预和支架相关并发症。当影像学证实胆囊管通畅时,EUS-GB可作为MDBO患者胆道引流的主要入路或挽救策略。
期刊介绍:
Digestive Diseases and Sciences publishes high-quality, peer-reviewed, original papers addressing aspects of basic/translational and clinical research in gastroenterology, hepatology, and related fields. This well-illustrated journal features comprehensive coverage of basic pathophysiology, new technological advances, and clinical breakthroughs; insights from prominent academicians and practitioners concerning new scientific developments and practical medical issues; and discussions focusing on the latest changes in local and worldwide social, economic, and governmental policies that affect the delivery of care within the disciplines of gastroenterology and hepatology.